While the US Supreme Court struck down Myriad Genetics' BRCA1 and BRCA2 gene patents in June, the University of California, San Francisco's Robert Nussbaum writes at Technology Review that monopolies on genetic data are still possible.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.

The new Riken president outlines some of his plans for the institute.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.